Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook

Dow Jones

11/08

By Terell Wright

Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries.

Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%.

The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet.

Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery.

The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share.

Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million.

Write to Terell Wright at terell.wright@wsj.com

(END) Dow Jones Newswires

November 07, 2025 15:05 ET (20:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581836445"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581836445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581836445?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581836445","market":"fut","top_or_hot":-1,"title":"Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n</p>\n<p>\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n</p>\n<p>\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n</p>\n<p>\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n</p>\n<p>\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n</p>\n<p>\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2025 15:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Medical Concepts Slides After Cut to Full-Year Revenue Outlook\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-08 04:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n</p>\n<p>\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n</p>\n<p>\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n</p>\n<p>\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n</p>\n<p>\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n</p>\n<p>\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2025 15:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMCI","symbol_name":"Treace Medical Concepts, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581836445","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581836445","pubTimestamp":1762545900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries.Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%.The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet.Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery.The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share.Revenue rose 11%, to $50.2 million, ahead","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMCI":"Treace Medical Concepts, Inc."},"translate_title":"Treace Medical Concepts下调全年收入预期后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMCI":1.5},"content_text":"By Terell Wright \n\n\n \n\n\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n\n\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n\n\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n\n\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n\n\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n\n\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n\n\n \n\n\n  Write to Terell Wright at terell.wright@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 15:05 ET (20:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}